Similarly, the pretreatment of azacitidine and DNMT1 depletion sensitized metastatic castration-resistant prostate cancer cells to the cytotoxic chemotherapeutics cabazitaxel and docetaxel [31,32]. The gene discussed is DNMT1; the disease is prostate cancer.